Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults.
In June 2021, the ACR released an updated guideline for the treatment of rheumatoid arthritis.1 The guideline underscores the role of methotrexate as a cornerstone therapy and emphasizes minimizing glucocorticoids, when possible. It also includes new recommendations for specific high-risk groups. Learn more in our article.
FEATURED ARTICLE: An Integrative Approach to the Treatment of Rheumatoid Arthritis
Treat to Target in Gout Monitoring & achievement of target serum urate levels By Jing Li & Gabriela Schmajuk, MD, MS Why was this study done? The ACR’s 2020 guideline for the management of gout recommends using a treat-to-target (T2T) approach to lower serum urate (SU). Using the ACR’s RISE registry, we examined the use… [Read More]
In 1949, the first description of patients with rheumatoid arthritis (RA) given cortisone sent shockwaves through the medical community, quickly capturing the public imagination as well. The paradigm-shifting report paved the way for the use of cortisone and related drugs in RA and many other medical conditions.1 The following is a discussion of some of… [Read More]
PHILADELPHIA—It is often the case that a holistic approach to the management of autoimmune disease is what patients are looking for and may indeed provide optimal care for these patients. At ACR Convergence 2022, the session titled ACR Guideline for Physical, Psychosocial, Mind-Body and Nutritional Interventions for Rheumatoid Arthritis: An Integrative Approach to Treatment sought… [Read More]
PHILADELPHIA—William “Bill” R. Palmer, MD, MACR, was the first board-certified rheumatologist in Omaha, Neb., where he spent his entire 43-year clinical career and established himself as a great clinician, mentor and educator. Although Dr. Palmer passed away from metastatic thyroid cancer in August 2021, his memory lives on through his physician colleagues and at ACR… [Read More]
PHILADELPHIA—One of the great advancements in the field of rheumatology in recent years has been the increased understanding of various stages of disease in rheumatoid arthritis (RA), including what is termed subclinical rheumatoid arthritis. However, questions remain regarding whether to treat patients with subclinical disease and whether treatment of these patients has implications in preventing… [Read More]
In this overview of clinical updates in rheumatology in the last year, high-impact studies were discussed, including the GLORIA, ORAL Surveillance and MIRROR trials.... [Read More]
D espite an expanding armamentarium of disease-modifying treatments for rheumatoid arthritis (RA), some patients with RA remain symptomatic.1 Current treatment guidelines from both the ACR and the European Alliance of Associations for Rheumatology (EULAR) recommend treat-to-target strategies to achieve remission or low disease activity, and patients want to feel better.2,3 So how can we best… [Read More]
A study has shown that in untreated patients with early RA, treatment with methotrexate combined with the biologic therapies abatacept or certolizumab-pegol resulted in greater CDAI remission rates than active conventional therapy with prednisolone, sulfasalazine or hydroxychloroquine.... [Read More]
A EULAR 2022 abstract session looked at several studies that seek to increase understanding of RA pathogenesis & identify patients at risk for disease progression.... [Read More]
Dr. Jacob van Laar took a deep dive into the what defines difficult-to-treat rheumatoid arthritis & how to approach these patients during EULAR 2022.... [Read More]